BRCA1 and cancer: This approach has resulted in the identification of many pathogenic (Path) and likely pathogenic (LPath) variants, and variants of unknown significance (VUSs) from genes other than BRCA1 and BRCA2. Path and LPath variants are important in drug discovery and treatment options, while VUSs could be significant in the initiation of more studies to identify their cancer-causing roles.